Hemophilia A Clinical Trial
Official title:
Comparing the Burden of Illness of Hemophilia in the Developing and the Developed World: The Sao Paulo - Toronto Hemophilia Study
NCT number | NCT01217255 |
Other study ID # | 1000020214 |
Secondary ID | |
Status | Completed |
Phase | |
First received | |
Last updated | |
Start date | September 2010 |
Est. completion date | October 2013 |
Verified date | June 2018 |
Source | The Hospital for Sick Children |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
Because of high cost, persons with hemophilia in many developing countries cannot afford
adequate treatment. For example, many persons with hemophilia in India and China are only
rarely treated with factor replacement in response to bleeds, and as a result many have
developed significant arthropathy and disability. A pilot study in China estimated the mean
Hemophilia Joint Health Score (HJHS) at 13.1 (SD 9.03) suggesting that these children had
highly prevalent, severe joint disease. The lack of relationship between the HJHS and
treatment history suggests overall inadequate therapy.
The proposed study will quantify the burden of arthropathy, physical disability, and quality
of life (QoL) in boys with hemophilia in Brazil - where comprehensive treatment is just
beginning to be widely available. This study will also provide an opportunity to compare
these outcomes to those observed in Canada, where the dominant therapy has become life-long
prophylaxis.
Status | Completed |
Enrollment | 100 |
Est. completion date | October 2013 |
Est. primary completion date | October 2013 |
Accepts healthy volunteers | No |
Gender | Male |
Age group | 7 Years to 18 Years |
Eligibility |
Inclusion criteria - Hemophilia A or B moderate or severe as determined by serum factor activity = 5% - Age 7 - 18 yrs. inclusive - At least one parent or guardian fluent in written Portuguese or English and able to complete the study outcome questionnaires. Exclusion criteria - None (Children with inhibitors will be allowed into the study for 2 reasons: i) our study aims to document the health of persons with hemophilia in a generalizable way, ii) not all children will have had inhibitor testing done.) |
Country | Name | City | State |
---|---|---|---|
Brazil | Universidade Estadual de Campinas, UNICAMP | Campinas | Sao Paulo |
Brazil | Hospital das Clinicas da Faculdade de Medicina da Universidade de Sao Paulo | Sao Paulo | |
Brazil | Universidade Federal de São Paulo (UNIFESP) | Sao Paulo | |
Canada | The Hospital for Sick Children | Toronto | Ontario |
Lead Sponsor | Collaborator |
---|---|
The Hospital for Sick Children |
Brazil, Canada,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Burden of Illness | Burden of disability for Brazilian and Canadian children will be be determined by analysis of the following domains: Structure and Function Domain (HJHS score, Biometrics,Radiographs) Activity Domain (ASK and FISH scales) Participation Domain (CHO-KLAT and PedsQL Quality of Life Questionnaire) Health Condition Domain (bleeding frequency) Personal Factors Domain (Ethnicity, level of education of parent/guardian, habitual exercise) Environmental Domain (Household income of parent/guardian) |
3 years | |
Secondary | The Activity Scale for Kids (ASK) | Children's self-reported activities will be measured with the Activity Scales for Kids (ASK) as part of the Activity Domain | Day 1 | |
Secondary | Functional Independence Scale for Hemophilia (FISH) | Observed activity limitations will be measured with the FISH as part of the Activity Domain. The FISH has been validated for use in developing countries. It consists of observed activities of daily living that are scored for quality. |
Day 1 | |
Secondary | Hemophilia Joint Health Score (HJHS) | The HJHS is a valid and reliable scored measure of joint structural limitations as applied to the index joints. This score will be a measure of the Structure and function domain. |
Day 1 | |
Secondary | Radiographs | Radiographs will be taken of all 6 index joints. This will be done as part of the structure and function domain. | Day 1 | |
Secondary | Canadian Haemophilia Outcomes - Kids Life Assessment Tool (CHO-KLAT) | After the completion of the pre-study cultural validation of the Brazilian translation of the CHO-KLAT scale, we will use it as a Quality of Life tool to measure the Participation domain | Day 1 | |
Secondary | Bleeding Frequency | Families will be interviewed to determine bleeding frequency in the last 6 months. This factor will be incorporated into the Health condition domain. | Day 1 | |
Secondary | Biometrics | The height and weight will be compared to national nomograms. | Days 1 | |
Secondary | Personal Factors | Ethnicity, level of education of the parent-guardian will be self-reported. | Day 1 | |
Secondary | Environmental domain | Whether a subject lives in a rural or urban area and household income will be recorded. | Day 1 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03834727 -
Characterizing the Impact and Treatment of Reproductive Tract Bleeding on Women and Post-menarchal Girls With Bleeding Disorders
|
||
Completed |
NCT03191799 -
A Study to Evaluate the Safety and Tolerability of Prophylactic Emicizumab in Hemophilia A Patients With Inhibitors
|
Phase 3 | |
Completed |
NCT01599819 -
BAX 855 Dose-Escalation Safety Study
|
Phase 1 | |
Terminated |
NCT04541628 -
Safety & Efficacy of Encapsulated Allogeneic FVIII Cell Therapy in Haemophilia A
|
Phase 1/Phase 2 | |
Completed |
NCT02847637 -
A Clinical Trial to Evaluate Prophylactic Emicizumab Versus no Prophylaxis in Hemophilia A Participants Without Inhibitors
|
Phase 3 | |
Completed |
NCT04072237 -
Study of Coagulation Faction VIIa Variant Marzeptacog Alfa (Activated) in Adult Subjects With Hemophilia
|
Phase 1 | |
Completed |
NCT04085458 -
Study to Gain More Information on How Safe and Effective Jivi Works in Patients With Severe Hemophilia A (Post-marketing Investigation)
|
Phase 4 | |
Completed |
NCT04565236 -
A Post Approval Commitment Study to Gain More Information on How Safe and Effective KOVALTRY is in Chinese Children, Adolescents /Adults With Severe Hemophilia A
|
Phase 4 | |
Recruiting |
NCT05987449 -
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of NXT007 in Persons With Severe or Moderate Hemophilia A
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT04621916 -
Preventing Inhibitor Recurrence Indefinitely
|
Phase 4 | |
Not yet recruiting |
NCT02888223 -
Pharmacokinetic Study of SCT800 in Previously Treated Patients With Hemophilia A
|
Phase 1 | |
Completed |
NCT02528968 -
National Study of a Pharmacokinetic-Focused Educational Package for Patients With Severe Haemophilia A
|
N/A | |
Completed |
NCT02225483 -
Phenotypic Heterogeneity in Hemophilia A: An Investigation of the Role of Platelet Function
|
N/A | |
Completed |
NCT02199717 -
An Institutional Pilot Study to Investigate Physical Activity Patterns in Boys With Hemophilia
|
N/A | |
Terminated |
NCT00995046 -
Individually Tailored Prophylaxis in Patients With Severe Hemophilia A
|
N/A | |
Completed |
NCT00969319 -
Effekt-2 - Efficacy and Safety of Long-term Treatment With KOGENATE® FS in Latin America
|
N/A | |
Completed |
NCT00868530 -
Study Evaluating On-Demand Treatment Of Xyntha In Chinese Subjects
|
Phase 3 | |
Completed |
NCT00839202 -
Activity and Content of Factor VIII (FVIII) in Human Plasma: The Assessment of a Novel Immunoassay
|
N/A | |
Completed |
NCT00629837 -
Pharmacokinetics and Safety of a Single Intravenous Infusion of BAY 79-4980
|
Phase 1 | |
Completed |
NCT02093741 -
ADVATE 2 mL Post-Authorization Safety Surveillance (PASS)
|